Compounds > wzb117
Page last updated: 2024-11-13

wzb117

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

WZB117: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID46830365
CHEMBL ID3092944
SCHEMBL ID19183300
MeSH IDM0579637

Synonyms (28)

Synonym
nsc-750937
nsc750937
CHEMBL3092944 ,
bdbm50444088
S7927
1223397-11-2
[3-fluoro-2-(3-hydroxybenzoyl)oxyphenyl] 3-hydroxybenzoate
AC-32898
3-fluoro-1,2-phenylene bis(3-hydroxybenzoate)
wzb 117
wzb-117, >=98% (hplc)
SCHEMBL19183300
wzb117
HY-19331
CS-0015243
AKOS032945159
BCP24665
wzb-117
EX-A1492
BS-14666
CCG-268262
C71842
benzoic acid, 3-hydroxy-, 1,1'-(3-fluoro-1,2-phenylene) ester
A900965
BW167833
3-fluoro-2-(3-hydroxybenzoyloxy)phenyl 3-hydroxybenzoate
EN300-114512
Z1443585951
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)IC50 (µMol)10.90000.00492.99549.9920AID1058218
Solute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)IC50 (µMol)2.50002.50003.20003.9000AID1794828
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (35)

Processvia Protein(s)Taxonomy
central nervous system developmentSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
response to hypoxiaSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
female pregnancySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
long-chain fatty acid import across plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
L-ascorbic acid metabolic processSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
cerebral cortex developmentSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
cellular response to glucose starvationSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
xenobiotic transportSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
photoreceptor cell maintenanceSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
protein-containing complex assemblySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
cellular response to mechanical stimulusSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
cellular hyperosmotic responseSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
glucose import across plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
response to Thyroglobulin triiodothyronineSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
glucose transmembrane transportSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
glucose importSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
response to insulinSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
dehydroascorbic acid transportSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
learning or memorySolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
positive regulation of brain-derived neurotrophic factor receptor signaling pathwaySolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
glucose homeostasisSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
short-term memorySolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
long-term memorySolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
carbohydrate metabolic processSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
amylopectin biosynthetic processSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
cellular response to insulin stimulusSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
glucose homeostasisSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
glucose import in response to insulin stimulusSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
response to ethanolSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
glucose importSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
brown fat cell differentiationSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
white fat cell proliferationSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
cellular response to tumor necrosis factorSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
cellular response to hypoxiaSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
cellular response to osmotic stressSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
regulation of synaptic vesicle budding from presynaptic endocytic zone membraneSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
glucose transmembrane transportSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
dehydroascorbic acid transportSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (9)

Processvia Protein(s)Taxonomy
long-chain fatty acid transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
glucose transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
protein bindingSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
kinase bindingSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
dehydroascorbic acid transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
identical protein bindingSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
D-glucose transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
glucose transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
protein bindingSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
glucose uniporter activitySolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
D-glucose transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (34)

Processvia Protein(s)Taxonomy
plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
Golgi membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
female germ cell nucleusSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
photoreceptor inner segmentSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
female pronucleusSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
cytosolSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
caveolaSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
intercalated discSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
basolateral plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
Z discSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
midbodySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
cortical actin cytoskeletonSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
sarcolemmaSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
melanosomeSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
extracellular exosomeSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
blood microparticleSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
presynapseSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
glucose transporter complexSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
basolateral plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
plasma membraneSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
multivesicular bodySolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
trans-Golgi networkSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
cytosolSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
plasma membraneSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
clathrin-coated pitSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
external side of plasma membraneSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
endomembrane systemSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
vesicle membraneSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
membraneSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
sarcoplasmic reticulumSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
clathrin-coated vesicleSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
trans-Golgi network transport vesicleSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
T-tubuleSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
cytoplasmic vesicle membraneSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
insulin-responsive compartmentSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
sarcolemmaSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
membrane raftSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
perinuclear region of cytoplasmSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
extracellular exosomeSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
presynapseSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
endomembrane systemSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
perinuclear region of cytoplasmSolute carrier family 2, facilitated glucose transporter member 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID1721640Antiproliferative activity against human NCI-H1299 cells assessed as reduction in cell viability at 30 uM incubated for 48 hrs by MTT assay relative to control2020Bioorganic & medicinal chemistry letters, 09-15, Volume: 30, Issue:18
Isosteres of ester derived glucose uptake inhibitors.
AID1721639Inhibition of glucose uptake in human NCI-H1299 cells at 30 uM incubated for 10 mins followed by L-[3H]2-deoxyglucose and glucose addition and measured after 30 mins by scintillation counting method relative to control2020Bioorganic & medicinal chemistry letters, 09-15, Volume: 30, Issue:18
Isosteres of ester derived glucose uptake inhibitors.
AID1721637Antitumor activity in human A549 cells xenografted in NU/J mouse assessed as reduction in tumor volume at 10 mg/kg, ip administered for 10 weeks and measured for every 7 day relative to control2020Bioorganic & medicinal chemistry letters, 09-15, Volume: 30, Issue:18
Isosteres of ester derived glucose uptake inhibitors.
AID1167903Inhibition of glucose transporter GLUT (unknown origin) by standard glucose uptake assay2014Bioorganic & medicinal chemistry letters, Nov-01, Volume: 24, Issue:21
An update on therapeutic opportunities offered by cancer glycolytic metabolism.
AID1058218Inhibition of GLUT1 in human H1299 cells assessed as inhibition of 2-deoxy-D-[3H]-glucose uptake incubated for 15 mins prior to 2-deoxy-D-[3H]-glucose addition measured after 30 mins by liquid scintillation counting analysis2013Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24
Oxime-based inhibitors of glucose transporter 1 displaying antiproliferative effects in cancer cells.
AID1073029Inhibition of GLUT-1 in human H1299 cells assessed as 2-deoxy-D-[3H]glucose uptake at 30 uM incubated for 15 mins prior to 2-deoxy-D-[3H]glucose challenge measured after 10 mins by liquid scintillation counting analysis (Rvb = 100%)2014Journal of natural products, Mar-28, Volume: 77, Issue:3
Constituents of an extract of Cryptocarya rubra housed in a repository with cytotoxic and glucose transport inhibitory effects.
AID1167906Antitumor activity against human A549 cells in in-vivo xenograft model assessed as reduction in tumor volume at 10 mg/kg/day, ip2014Bioorganic & medicinal chemistry letters, Nov-01, Volume: 24, Issue:21
An update on therapeutic opportunities offered by cancer glycolytic metabolism.
AID1058216Cytotoxicity against human H1299 cells assessed as growth inhibition after 48 hrs by MTT assay2013Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24
Oxime-based inhibitors of glucose transporter 1 displaying antiproliferative effects in cancer cells.
AID1721641Stability in human serum assessed as reduction in A549 cell viability at 30 uM measured upto 12 hrs by resazurin assay2020Bioorganic & medicinal chemistry letters, 09-15, Volume: 30, Issue:18
Isosteres of ester derived glucose uptake inhibitors.
AID1425908Antitumor activity against human A549 cells xenografted in NU/J nude mouse assessed as inhibition of tumor volume at 10 mg/kg, ip administered daily for 10 weeks measured every 7 days during compound dosing relative to control2016MedChemComm, Sep-01, Volume: 7, Issue:9
Anticancer agents interacting with membrane glucose transporters.
AID1721638Stability in human serum assessed as compound remaining incubated for 1 hr2020Bioorganic & medicinal chemistry letters, 09-15, Volume: 30, Issue:18
Isosteres of ester derived glucose uptake inhibitors.
AID1167905Cytotoxicity against human H1299 cells assessed as reduction in cell viability2014Bioorganic & medicinal chemistry letters, Nov-01, Volume: 24, Issue:21
An update on therapeutic opportunities offered by cancer glycolytic metabolism.
AID1167904Growth inhibition of human H1299 cells2014Bioorganic & medicinal chemistry letters, Nov-01, Volume: 24, Issue:21
An update on therapeutic opportunities offered by cancer glycolytic metabolism.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (30)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's20 (66.67)24.3611
2020's10 (33.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.83

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.83 (24.57)
Research Supply Index3.43 (2.92)
Research Growth Index4.64 (4.65)
Search Engine Demand Index31.18 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (28.83)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (3.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other29 (96.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
3-hydroxybutyric acid
3-Hydroxybutyric Acid: BUTYRIC ACID substituted in the beta or 3 position. It is one of the ketone bodies produced in the liver.. 3-hydroxybutyric acid : A straight-chain 3-hydroxy monocarboxylic acid comprising a butyric acid core with a single hydroxy substituent in the 3- position; a ketone body whose levels are raised during ketosis, used as an energy source by the brain during fasting in humans. Also used to synthesise biodegradable plastics.		2.610(omega-1)-hydroxy fatty acid;
3-hydroxy monocarboxylic acid;
hydroxybutyric acid		human metabolite
fluorouracil
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.		2.110nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
gossypol
Gossypol: A dimeric sesquiterpene found in cottonseed (GOSSYPIUM). The (-) isomer is active as a male contraceptive (CONTRACEPTIVE AGENTS, MALE) whereas toxic symptoms are associated with the (+) isomer.		2.1310
phloretin
[no description available]		2.0810dihydrochalconesantineoplastic agent;
plant metabolite
sodium fluoride
[no description available]		2.3110fluoride saltmutagen
3-o-methylglucose
3-O-Methylglucose: A non-metabolizable glucose analogue that is not phosphorylated by hexokinase. 3-O-Methylglucose is used as a marker to assess glucose transport by evaluating its uptake within various cells and organ systems. (J Neurochem 1993;60(4):1498-504). 3-O-methyl-D-glucose : A D-aldohexose that is D-glucose in which the hydrogen of the hydroxy group at position 3 has been substituted by a methyl group. It is a non-metabolisable glucose analogue that is not phosphorylated by hexokinase and is used as a marker to assess glucose transport by evaluating its uptake within various cells and organ systems.		2.1310D-aldohexose derivative
silybin
silibinin : A flavonolignan isolated from milk thistle, Silybum marianum, that has been shown to exhibit antioxidant and antineoplastic activities.		2.1310aromatic ether;
benzodioxine;
flavonolignan;
polyphenol;
secondary alpha-hydroxy ketone		antineoplastic agent;
antioxidant;
hepatoprotective agent;
plant metabolite
paclitaxel
Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).		2.110taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
triazoles
Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.		2.21101,2,3-triazole
fluorodeoxyglucose f18
Fluorodeoxyglucose F18: The compound is given by intravenous injection to do POSITRON-EMISSION TOMOGRAPHY for the assessment of cerebral and myocardial glucose metabolism in various physiological or pathological states including stroke and myocardial ischemia. It is also employed for the detection of malignant tumors including those of the brain, liver, and thyroid gland. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1162)		2.15102-deoxy-2-((18)F)fluoro-D-glucose;
2-deoxy-2-fluoro-aldehydo-D-glucose
deoxyglucose
Deoxyglucose: 2-Deoxy-D-arabino-hexose. An antimetabolite of glucose with antiviral activity.. deoxyglucose : A deoxyhexose comprising glucose having at least one hydroxy group replaced by hydrogen.		2.5720
imatinib mesylate
imatinib methanesulfonate : A methanesulfonate (mesylate) salt that is the monomesylate salt of imatinib. Used for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours.		2.4110methanesulfonate saltanticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor
naringenin
(S)-naringenin : The (S)-enantiomer of naringenin.		2.1310(2S)-flavan-4-one;
naringenin		expectorant;
plant metabolite
xanthohumol
xanthohumol: from hop plant, Humulus lupulus. xanthohumol : A member of the class of chalcones that is trans-chalcone substituted by hydroxy groups at positions 4, 2' and 4', a methoxy group at position 6' and a prenyl group at position 3'. Isolated from Humulus lupulus, it induces apoptosis in human malignant glioblastoma cells.		2.1310aromatic ether;
chalcones;
polyphenol		anti-HIV-1 agent;
antineoplastic agent;
antiviral agent;
apoptosis inducer;
EC 2.3.1.20 (diacylglycerol O-acyltransferase) inhibitor;
metabolite
fasentin
fasentin: chemical sensitizer to death receptor stimuli FAS; structure in first source		2.1710
stf-31
STF-31: antineoplastic		2.5520
cobaltous chloride
cobaltous chloride: RN given refers to unlabeled cpd; RN in Chemline for cobalt trichloride: 10241-04-0; RN for 60-labeled cpd: 14543-09-0; RN for 57-labeled cpd: 164113-89-1; RN for 58-labeled cpd: 29377-09-1; structure. cobalt dichloride : A cobalt salt in which the cobalt metal is in the +2 oxidation state and the counter-anion is chloride. It is used as an indicator for water in desiccants.		2.610cobalt salt;
inorganic chloride		allergen;
calcium channel blocker;
sensitiser;
two-colour indicator
4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione
4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione: a GSK3beta inhibitor. TDZD-8 : A member of the class of thiadiazolidines that is 1,2,4-thiadiazolidine-3,5-dione which is substituted by a methyl group at position 2 and by a benzyl group at position 4. It is a non-ATP competitive inhibitor of glycogen synthase kinase 3beta (GSK3beta). An experimental compound which was being developed for the potential treatment of Alzheimer's disease.		2.610benzenes;
thiadiazolidine		anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
neuroprotective agent
osteoprotegerin
Osteoprotegerin: A secreted member of the TNF receptor superfamily that negatively regulates osteoclastogenesis. It is a soluble decoy receptor of RANK LIGAND that inhibits both CELL DIFFERENTIATION and function of OSTEOCLASTS by inhibiting the interaction between RANK LIGAND and RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B.		2.1710long-chain fatty acid
quercetin
[no description available]		2.55207-hydroxyflavonol;
pentahydroxyflavone		antibacterial agent;
antineoplastic agent;
antioxidant;
Aurora kinase inhibitor;
chelator;
EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor;
geroprotector;
phytoestrogen;
plant metabolite;
protein kinase inhibitor;
radical scavenger
kaempferol
[no description available]		2.13107-hydroxyflavonol;
flavonols;
tetrahydroxyflavone		antibacterial agent;
geroprotector;
human blood serum metabolite;
human urinary metabolite;
human xenobiotic metabolite;
plant metabolite
genistein
[no description available]		2.13107-hydroxyisoflavonesantineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
geroprotector;
human urinary metabolite;
phytoestrogen;
plant metabolite;
tyrosine kinase inhibitor
myricetin
[no description available]		2.13107-hydroxyflavonol;
hexahydroxyflavone		antineoplastic agent;
antioxidant;
cyclooxygenase 1 inhibitor;
food component;
geroprotector;
hypoglycemic agent;
plant metabolite
cytochalasin b
Cytochalasin B: A cytotoxic member of the CYTOCHALASINS.. cytochalasin B : An organic heterotricyclic compound, that is a mycotoxin which is cell permeable an an inhibitor of cytoplasmic division by blocking the formation of contractile microfilaments.		2.5520cytochalasin;
lactam;
lactone;
organic heterotricyclic compound		actin polymerisation inhibitor;
metabolite;
mycotoxin;
platelet aggregation inhibitor
3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one
3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one: 6-phosphofructo-2-kinase-fructose-2,6-bisphosphatase isozymes inhibitor; structure in first source		3.1910enone;
pyridines		angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
autophagy inducer;
EC 2.7.1.105 (6-phosphofructo-2-kinase) inhibitor
vlx600
VLX600: has antineoplastic activity; structure in first source		2.2110
azd3965
AZD3965: a monocarboxylate transporter-1 inhibitor with antineoplastic activity; structure in first source		3.1910
cryptocaryone
cryptocaryone: inhibitor of the NF-kappaB activation pathway from Cryptocarya rugulosa; structure in first source		2.5220benzofurans
nad
NAD(1-) : An anionic form of nicotinamide adenine dinucleotide arising from deprotonation of the two OH groups of the diphosphate moiety.		2.1710organophosphate oxoanioncofactor;
human metabolite;
hydrogen acceptor;
Saccharomyces cerevisiae metabolite
glucopiericidin a
glucopiericidin A: from Streptomyces pactum S48727 as co-metabolite of piericidin A(1); structure given in first source; glycoside antibiotic		2.1310
methyl 1-hydroxy-6-phenyl-4-(trifluoromethyl)-1h-indole-2-carboxylate
methyl 1-hydroxy-6-phenyl-4-(trifluoromethyl)-1H-indole-2-carboxylate: inhibits lactate dehydrogenase A; structure in first source		3.6120
tigecycline
[no description available]		2.2110
ConditionIndicatedRelationship StrengthStudiesTrials
Benign Neoplasms
[description not available]		03.730
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		03.730
Gastrointestinal Stromal Neoplasm
[description not available]		02.4110
Cancer of Gastrointestinal Tract
[description not available]		02.4110
Gastrointestinal Stromal Tumors
All tumors in the GASTROINTESTINAL TRACT arising from mesenchymal cells (MESODERM) except those of smooth muscle cells (LEIOMYOMA) or Schwann cells (SCHWANNOMA).		02.4110
Acute Confusional Senile Dementia
[description not available]		02.920
Alzheimer Disease
A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)		02.920
Anoxemia
[description not available]		02.610
Breast Cancer
[description not available]		02.8930
Hypoxia
Sub-optimal OXYGEN levels in the ambient air of living organisms.		02.610
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.8930
Neuroblastoma
A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)		02.7220
Dysplastic Nevus Syndrome, Hereditary
[description not available]		02.610
Malignant Melanoma
[description not available]		02.6120
Melanoma
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)		07.6120
Central Retinal Edema, Cystoid
[description not available]		02.610
Diabetic Retinopathy
Disease of the RETINA as a complication of DIABETES MELLITUS. It is characterized by the progressive microvascular complications, such as ANEURYSM, interretinal EDEMA, and intraocular PATHOLOGIC NEOVASCULARIZATION.		02.610
Macular Edema
Fluid accumulation in the outer layer of the MACULA LUTEA that results from intraocular or systemic insults. It may develop in a diffuse pattern where the macula appears thickened or it may acquire the characteristic petaloid appearance referred to as cystoid macular edema. Although macular edema may be associated with various underlying conditions, it is most commonly seen following intraocular surgery, venous occlusive disease, DIABETIC RETINOPATHY, and posterior segment inflammatory disease. (From Survey of Ophthalmology 2004; 49(5) 470-90)		02.610
Epithelial Ovarian Cancer
[description not available]		02.2110
Cancer of Ovary
[description not available]		02.2110
Carcinoma, Ovarian Epithelial
A malignant neoplasm that originates in cells on the surface EPITHELIUM of the ovary and is the most common form of ovarian cancer. There are five histologic subtypes: papillary serous, endometrioid, mucinous, clear cell, and transitional cell. Mutations in BRCA1, OPCML, PRKN, PIK3CA, AKT1, CTNNB1, RRAS2, and CDH1 genes are associated with this cancer.		02.2110
Ovarian Neoplasms
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.		02.2110
Adenocarcinoma, Basal Cell
[description not available]		02.8530
Innate Inflammatory Response
[description not available]		02.3110
Cancer of Pancreas
[description not available]		03.2340
Carcinoma, Ductal, Pancreatic
[description not available]		02.3110
Adenocarcinoma
A malignant epithelial tumor with a glandular organization.		02.8530
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.3110
Pancreatic Neoplasms
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).		03.2340
Carcinoma, Pancreatic Ductal
Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.		02.3110
Lung Adenocarcinoma
[description not available]		02.1510
Carcinoma, Non-Small Cell Lung
[description not available]		02.1510
Carcinoma, Epidermoid
[description not available]		02.1510
Cancer of Lung
[description not available]		02.1510
Adenocarcinoma of Lung
A carcinoma originating in the lung and the most common lung cancer type in never-smokers. Malignant cells exhibit distinct features such as glandular epithelial, or tubular morphology. Mutations in KRAS, EGFR, BRAF, and ERBB2 genes are associated with this cancer.		02.1510
Carcinoma, Non-Small-Cell Lung
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.		02.1510
Carcinoma, Squamous Cell
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)		02.1510
Lung Neoplasms
Tumors or cancer of the LUNG.		02.1510
Autoimmune Diabetes
[description not available]		02.1710
Diabetes Mellitus, Type 1
A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.		02.1710
Infections, Plasmodium
[description not available]		02.1710
Malaria
A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia.		02.1710
Disease Exacerbation
[description not available]		02.1710
Colorectal Cancer
[description not available]		02.1710
Colorectal Neoplasms
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.		02.1710
Cancer of Colon
[description not available]		02.110
Colonic Neoplasms
Tumors or cancer of the COLON.		02.110
Cancer of Liver
[description not available]		02.1110
B16 Melanoma
[description not available]		02.1110
Cancer of Skin
[description not available]		02.1110
Liver Neoplasms
Tumors or cancer of the LIVER.		02.1110
Skin Neoplasms
Tumors or cancer of the SKIN.		02.1110